Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase 3, Open-Label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
A study about extended Nexplanon use in females 18-35 years old
Sponsor:Merck Sharpe & Dohme Corp
Enrolling:Female Patients Only
Clinic Visits:11
Age Range:Between 18 and 35 years old
IRB Number:AAAT3564
U.S. Government ID:NCT04626596
Contact: Yessica Estrella Vanterpool: 212-305-8031 / ye2193@cumc.columbia.edu
Additional Study Information:

Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.

Do You Qualify?
Are you currently using the Nexplanon implant as your current contraceptive method?YesNo
Would you be willing to use the Nexplanon as your only method of contraception during your participation in the study?YesNo
Are you planning to avoid pregnancy for the next 2 years?YesNo
Submit
Cancel
Investigator
Paula Castano, MD, MPH
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Yessica Estrella Vanterpool
Email: ye2193@cumc.columbia.edu
Phone: 212-305-8031